2-Methyl-3-Nitrophenylacetic Acid CAS 23876-15-5 Purity >99.5% (HPLC) Ropinirole Hydrochloride Intermediate

Short Description:

Chemical Name: 2-Methyl-3-Nitrophenylacetic Acid 

CAS: 23876-15-5

Purity: >99.5% (HPLC)

Appearance: Off-White or Pale Yellow Powder 

Intermediate of Ropinirole Hydrochloride (CAS: 91374-20-8)

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Manufacturer Supply With High Quality, Commercial Production 
Chemical Name: 2-Methyl-3-Nitrophenylacetic Acid CAS: 23876-15-5

Chemical Properties:

Chemical Name 2-Methyl-3-Nitrophenylacetic Acid
Synonyms 2-Methyl-3-Nitro-Benzeneacetic Acid; Ropinirole Intermediate 1; (3-Nitro-o-tolyl)acetic Acid; 2-(2-methyl-3-nitrophenyl)acetic acid
CAS Number 23876-15-5
CAT Number RF-PI1196
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C9H9NO4
Molecular Weight 195.17 
Melting Point 131.0~136.0℃
Solubility Soluble in Methanol
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance Off-White or Pale Yellow Powder
Purity / Analysis Method >99.5% (HPLC) 
Melting Point 130.0~137.0℃
Loss on Drying <0.50%
Single Impurity ≤0.20%
Total Impurities <0.50%
Test Standard Enterprise Standard
Usage Intermediate of Ropinirole Hydrochloride (CAS: 91374-20-8)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.

Advantages:

1

FAQ:

Application:

2-Methyl-3-Nitrophenylacetic Acid (CAS: 23876-15-5) is an intermediate of Ropinirole Hydrochloride (CAS: 91374-20-8). Ropinirole Hydrochloride was launched in the UK as a monotherapy or in combination with low-dose levodopa for the treatment of early-stage idiopathic Parkinson's disease. Ropinirole Hydrochloride is also used for the treatment of moderate to severe Restless Legs Syndrome (RLS). FDA approved the first generic drug of Ropinirole Hydrochloride, developed by GlaxoSmithKline(GSK). An antiparkinsonian agent. A selective dopamine D2-receptor agonist.

  • Write your message here and send it to us